All
'A Breath of Fresh Air': FDA's Cosela Approval May Improve Quality of Life in Lung Cancer
March 12th 2021The FDA’s recent approval of Cosela to reduce the frequency of chemotherapy-induced bone marrow suppression in adults who are receiving certain types of chemotherapy for extensive-stage small cell lung cancer is a “breath of fresh air,” according to an expert.
Approval of Orgovyx ‘Extremely Significant’ for Patients with Advanced Prostate Cancer
March 11th 2021The Food and Drug Administration’s recent approval of the first oral hormone therapy, Orgovyx, for the treatment of advanced prostate cancer has positioned the drug to become a standard of care for patients, according to an expert.
‘The Future is Brighter’ for Triple-Negative Breast Cancer
March 11th 2021Triple-negative breast cancer, which is found in 15%-20% of invasive breast cancers, is a challenge when it comes to treatment, but thanks to new drug approvals and therapy regimens, the treatment landscape has progressed in recent years, according to an expert.
How TikTok Helped One Cancer Survivor Find Connection and Community
March 11th 2021This week on the “CURE® Talks Cancer” podcast, we spoke with lymphoma survivor Nina Luker about what it was like to receive a diagnosis at age 24, and how sharing her story with nearly 200,000 supporters on TikTok and Instagram led her to find purpose with the Lymphoma Research Foundation.
How Targeted Therapies Are Changing the Breast Cancer Treatment Landscape
March 11th 2021Targeted therapies that attack cancer in a more precise way than traditional chemotherapy are being used more often in the field of breast cancer, but the solution in utilizing them lies within the patient-oncologist relationship, according to an expert from the Massachusetts General Hospital Cancer Center.
Looking at the Big Picture of Small Cell Lung Cancer
March 10th 2021An expert discusses ways that small cell lung cancer is diagnosed, how to treat it and how to pivot if the disease spreads or recurs. He also focuses on efforts in the clinical trial space to potentially treat patients more effectively.
Cabometyx-Opdivo Is ‘One of the New Standards of Care’ in Treating Kidney Cancer Subtype
March 9th 2021The combination of Cabometyx (cabozantinib) plus Opdivo (nivolumab) “is certainly going to become one of the new standards of care” for the treatment of advanced renal cell carcinoma now that the regimen is approved, according to an expert from the Dana-Farber Cancer Institute.
Cancer Survivor Offers Tips on How to Help Loved Ones Get Through Difficult Times
March 9th 2021Nearly one year ago to the day, 24-year-old Nina Luker was completely blindsided by a diagnosis of non-Hodgkin lymphoma. But after powering through treatments in the thick of the COVID-19 pandemic, Luker is now cancer-free and offering advice to those who may be looking for ways to help their loved ones through difficult times of their own.
‘Lost in Transition’ After Breast Cancer
March 9th 2021With more than 4 million breast cancer survivors in the U.S., survivorship care and understanding what happens to patients after surviving is of the utmost importance. An expert explains some side effects survivors may experience and treatments to help.
Death From Heart-Related Causes May Affect Cancer Survivors More Than the General Population
March 8th 2021More than half of the deaths assessed in this study were related to non-cancer-related causes such as cardiovascular disease compared with cancer-related causes, which may reflect a need for risk factor management for heart disease during survivorship.